Esperion Therapeutics Inc... (ESPR)
Esperion Therapeutics Statistics
Share Statistics
Esperion Therapeutics has 197.85M shares outstanding. The number of shares has increased by 15.62% in one year.
| Shares Outstanding | 197.85M |
| Shares Change (YoY) | 15.62% |
| Shares Change (QoQ) | 0.41% |
| Owned by Institutions (%) | 64.65% |
| Shares Floating | 194.37M |
| Failed to Deliver (FTD) Shares | 28.44K |
| FTD / Avg. Volume | 0.67% |
Short Selling Information
The latest short interest is 33.98M, so 17.24% of the outstanding shares have been sold short.
| Short Interest | 33.98M |
| Short % of Shares Out | 17.24% |
| Short % of Float | 17.42% |
| Short Ratio (days to cover) | 7.21 |
Valuation Ratios
The PE ratio is -7.96 and the forward PE ratio is -18.06. Esperion Therapeutics's PEG ratio is 0.09.
| PE Ratio | -7.96 |
| Forward PE | -18.06 |
| PS Ratio | 1.24 |
| Forward PS | 0.3 |
| PB Ratio | -1.06 |
| P/FCF Ratio | -17.18 |
| PEG Ratio | 0.09 |
Enterprise Valuation
Esperion Therapeutics Inc. has an Enterprise Value (EV) of 766.99M.
| EV / Earnings | -14.82 |
| EV / Sales | 2.31 |
| EV / EBITDA | 101.33 |
| EV / EBIT | 14.1 |
| EV / FCF | -32 |
Financial Position
The company has a current ratio of 1.37, with a Debt / Equity ratio of -0.77.
| Current Ratio | 1.37 |
| Quick Ratio | 0.99 |
| Debt / Equity | -0.77 |
| Total Debt / Capitalization | -326.6 |
| Cash Flow / Debt | -0.08 |
| Interest Coverage | 0.92 |
Financial Efficiency
Return on equity (ROE) is 0.13% and return on capital (ROIC) is -59.7%.
| Return on Equity (ROE) | 0.13% |
| Return on Assets (ROA) | -0.15% |
| Return on Capital (ROIC) | -59.7% |
| Revenue Per Employee | $1,093,138.16 |
| Profits Per Employee | $-170,213.82 |
| Employee Count | 304 |
| Asset Turnover | 0.97 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -40.3% in the last 52 weeks. The beta is 1.04, so Esperion Therapeutics's price volatility has been higher than the market average.
| Beta | 1.04 |
| 52-Week Price Change | -40.3% |
| 50-Day Moving Average | 1.8 |
| 200-Day Moving Average | 2.11 |
| Relative Strength Index (RSI) | 44.68 |
| Average Volume (20 Days) | 4.26M |
Income Statement
In the last 12 months, Esperion Therapeutics had revenue of 332.31M and earned -51.74M in profits. Earnings per share was -0.28.
| Revenue | 332.31M |
| Gross Profit | 332.31M |
| Operating Income | 54.4M |
| Net Income | -51.74M |
| EBITDA | 7.57M |
| EBIT | 54.4M |
| Earnings Per Share (EPS) | -0.28 |
Balance Sheet
The company has 144.76M in cash and 297.6M in debt, giving a net cash position of -152.84M.
| Cash & Cash Equivalents | 144.76M |
| Total Debt | 297.6M |
| Net Cash | -152.84M |
| Retained Earnings | -1.6B |
| Total Assets | 343.82M |
| Working Capital | 91.77M |
Cash Flow
In the last 12 months, operating cash flow was -23.65M and capital expenditures -317K, giving a free cash flow of -23.97M.
| Operating Cash Flow | -23.65M |
| Capital Expenditures | -317K |
| Free Cash Flow | -23.97M |
| FCF Per Share | -0.13 |
Margins
Gross margin is 100%, with operating and profit margins of 16.37% and -15.57%.
| Gross Margin | 100% |
| Operating Margin | 16.37% |
| Pretax Margin | -15.57% |
| Profit Margin | -15.57% |
| EBITDA Margin | 2.28% |
| EBIT Margin | 16.37% |
| FCF Margin | -7.21% |
Dividends & Yields
ESPR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -17.5% |
| FCF Yield | -7.57% |
Analyst Forecast
The average price target for ESPR is $4, which is 150% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 150% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -4.89 |
| Piotroski F-Score | 4 |